<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25189">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078414</url>
  </required_header>
  <id_info>
    <org_study_id>RFSU1</org_study_id>
    <nct_id>NCT02078414</nct_id>
  </id_info>
  <brief_title>Continued Use of Effective Contraception After Use of Emergency Contraception</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women using an emergency contraceptive method must use back up protection for 1-2 weeks
      depending on method. The Copper-IUD is the most effective emergency contraceptive method.
      The investigators wish to explore if women choosing the Cooper IUD have a higher frequency
      of use of an effective contraceptive method 3 months and 6 months after the use of an
      emergency contraceptive method than women who choose to use the emergency contraceptive pill
      EllaOne (ulipristal acetate).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Use of an effective contraceptive method</measure>
    <time_frame>6 months after emergency contraceptive use</time_frame>
    <safety_issue>No</safety_issue>
    <description>Use of pill, patch, ring, IUD, IUS, or injection 6 months after use of emergency contraceptive method</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Emergency Contraception</condition>
  <condition>Contraception</condition>
  <condition>Reproductive Health</condition>
  <arm_group>
    <arm_group_label>Ulipristal acetate</arm_group_label>
    <description>Women choosing EllaOne as emergency contraception</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copper IUD</arm_group_label>
    <description>Women choosing copper IUD as emergency contraception</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women without contraception or with a failed contraceptive method seeking emergency
        contraception
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women over 18 years

          -  eligible for all emergency contraception

        Exclusion Criteria:

          -  previous conisation

          -  known stenosis of the cervix

          -  signs of ongoing genital infection

          -  known uterine anomaly

          -  Known bleeding disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Helena Kopp Kallner, MD, PhD</last_name>
    <email>helena.kopp-kallner@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>RFSU clinic</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Kopp Kallner, MD, PhD</last_name>
      <email>helena.kopp-kallner@ki.se</email>
    </contact>
    <investigator>
      <last_name>Helena Kopp Kallner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>March 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Helena Kopp Kallner</investigator_full_name>
    <investigator_title>Consultant Obstetrics and Gynecology, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
